2 min read Science New data show Roche’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD) September 10, 2020 ENSPRYNG lowered relapse severity in double-blind periods of SAkura Phase III studies. Pooled data...
